These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

908 related items for PubMed ID: 29070763

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
    Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE, Yip L.
    Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165
    [Abstract] [Full Text] [Related]

  • 3. Integrating BRAFV600E mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma.
    Zhang Z, Zhang X, Yin Y, Zhao S, Wang K, Shang M, Chen B, Wu X.
    BMC Cancer; 2022 Apr 27; 22(1):461. PubMed ID: 35473554
    [Abstract] [Full Text] [Related]

  • 4. Conventional Ultrasound, Immunohistochemical Factors and BRAFV600E Mutation in Predicting Central Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma.
    Chen J, Li XL, Zhao CK, Wang D, Wang Q, Li MX, Wei Q, Ji G, Xu HX.
    Ultrasound Med Biol; 2018 Nov 27; 44(11):2296-2306. PubMed ID: 30100099
    [Abstract] [Full Text] [Related]

  • 5. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
    Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A.
    J Clin Endocrinol Metab; 2013 May 27; 98(5):E934-42. PubMed ID: 23533235
    [Abstract] [Full Text] [Related]

  • 6. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, Sebo TJ, Giordano TJ, Fahey TJ, Thompson GB, Gauger PG, Somervell H, Bishop JA, Eshleman JR, Schneider EB, Witwer KW, Umbricht CB, Zeiger MA.
    Thyroid; 2016 Apr 27; 26(4):532-42. PubMed ID: 26950846
    [Abstract] [Full Text] [Related]

  • 7. Predicting factors of central lymph node metastasis and BRAFV600E mutation in Chinese population with papillary thyroid carcinoma.
    Zhou SL, Guo YP, Zhang L, Deng T, Xu ZG, Ding C, Sun WC, Zhao YW, Kong LF.
    World J Surg Oncol; 2021 Jul 13; 19(1):211. PubMed ID: 34256769
    [Abstract] [Full Text] [Related]

  • 8. Integrating US-guided FNAB, BRAFV600E mutation, and clinicopathologic characteristics to predict cervical central lymph-node metastasis in preoperative patients with cN0 papillary thyroid carcinoma.
    Ma N, Tian HY, Yu ZY, Zhu X, Zhao DW.
    Eur Arch Otorhinolaryngol; 2023 Dec 13; 280(12):5565-5574. PubMed ID: 37540271
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
    Du J, Yang Q, Sun Y, Shi P, Xu H, Chen X, Dong T, Shi W, Wang Y, Song Z, Shang X, Tian X.
    Front Endocrinol (Lausanne); 2023 Dec 13; 14():1288527. PubMed ID: 38047112
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK, Chong A, Ha JM, Jung CK, O JH, Kim SH.
    Clin Endocrinol (Oxf); 2017 Jul 13; 87(1):73-79. PubMed ID: 28329426
    [Abstract] [Full Text] [Related]

  • 14. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
    Joo JY, Park JY, Yoon YH, Choi B, Kim JM, Jo YS, Shong M, Koo BS.
    J Clin Endocrinol Metab; 2012 Nov 13; 97(11):3996-4003. PubMed ID: 22930785
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M, Yan C, Xiao J, Wang T, Ling R.
    Diagn Pathol; 2019 Jul 12; 14(1):74. PubMed ID: 31300059
    [Abstract] [Full Text] [Related]

  • 17. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS.
    Surgery; 2015 Dec 12; 158(6):1500-11. PubMed ID: 26120069
    [Abstract] [Full Text] [Related]

  • 18. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAFV600E mutation.
    Lee YK, Park KH, Park SH, Kim KJ, Shin DY, Nam KH, Chung WY, Lee EJ.
    Head Neck; 2018 Oct 12; 40(10):2271-2279. PubMed ID: 29935011
    [Abstract] [Full Text] [Related]

  • 19. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
    Shi CL, Sun Y, Ding C, Lv YC, Qin HD.
    Genet Mol Res; 2015 Jul 03; 14(3):7377-85. PubMed ID: 26214416
    [Abstract] [Full Text] [Related]

  • 20. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
    Gao Q, Zhang W, Wang N, Duan H, Zhou Y, Zhang W, Zhao D.
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec 03; 29(23):2048-52. PubMed ID: 27101676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.